The third component of complement, C3, plays a central role in activation of the classical, alternative, and lectin pathways of complement activation. Recently, we have identified a 13-residue cyclic peptide (named Compstatin) that specifically binds to C3 and inhibits complement activation. To investigate the topology and the contribution of each critical residue to the binding of Compstatin to C3, we have now determined the solution structure using 2D NMR techniques; we have also synthesized substitution analogues and used these to study the structure-function relationships involved. Finally, we have generated an ensemble of a family of solution structures of the peptide with a hybrid distance geometry-restrained simulated-annealing methodology, using distance, dihedral angle, and 3JNH.H,-~o~pling constant restraints. The Compstatin structure contained a type I p-turn comprising the segment GlnS-Asp6-Trp7-Glys. Preference for packing of the hydrophobic side chains of Val3, Val4, and Trp' was observed. The generated structure was also analyzed for consistency using NMR parameters such as NOE connectivity patterns, 3JNH.H,-~o~pling constants, and chemical shifts. Analysis of Ala substitution analogues suggested that Val3, G l d , Asp6, Trp7, and Glys contribute significantly to the inhibitory activity of the peptide. Substitution of Gly' caused a 100-fold decrease in inhibitory potency. In contrast, substitution of Val4, His', His", and Arg" resulted in minimal change in the activity. These findings indicate that specific side-chain interactions and the &turn are critical for preservation of the conformational stability of Compstatin and they might be significant for maintaining the functional activity of Compstatin.
a rich architecture that provides a multiplicity of diverse ligand binding sites that are important in immune surveillance and immune response pathways (Lambris, 1990 (Lambris, , 1993 .
Inappropriate activation of complement may lead to host cell damage. Complement is implicated in several disease states, including various autoimmune diseases, and has been found to contribute to other clinical conditions, such as adult respiratory syndrome (Robbins et al., 1987) , stroke (Vasthare et al., 1993) , heart attack (Kilgore et al., 1994) , rejection following xenotransplantation (Wang et al., 1992) , and bum injuries (Gallinaro et al., 1992) . Complement-mediated tissue injury has also been found to result from bioincompatibility situations, such as those encountered in patients undergoing dialysis (Pekna et al., 1993) or cardiopulmonary bypass (Gillinov et al., 1994) .
Complement-mediated tissue injuries are mediated directly by the membrane attack complex, and indirectly by the generation of C3a and C5a (Hugh, 1990 : Ember et al., 1992 . These peptides induce damage through their effects on neutrophils (Ehrengruber et al., 1994) and mast cells (Ellati et al., 1994) . In vivo, regulation of complement at the C3 and C5 activation steps is provided by both plasma and membrane proteins. The plasma protein inhibitors are factor H and C4-binding protein, and the regulatory membrane proteins located on cell surfaces are complement receptors 1 (CRI), decay-accelerating factor (DAF), and membrane cofactor protein (MCP) (Holers et al., 1992) . These proteins inhibit the C3 and C5 convertases (multisubunit proteases) by promoting dissociation of the multisubunit complexes and/or by inactivating the complexes through proteolysis (catalyzed by factor I). Several pharmacological agents that regulate or modulate complement activity have been identified by in vitro assay, but most have been shown to be of low activity or toxic (Johnson, 1977; Reynard, 1980; Kalli et al., 1994; Morgan, 1994) .
Recently, we have used a phage-displayed random peptide library to identify peptides that bind C3 and inhibit complement. Using this approach, we have isolated a small cyclic inhibitory C3-binding peptide (now named Compstatin), which inactivates complement at a concentration approximately twice that of human C3 in normal human serum . The experiments performed to elucidate the mechanism of complement inhibition by Compstatin suggested that this peptide reversibly binds to native C3 to inhibit its activation and that the inhibition is not a result of sterically hindered access to the C3a/C3b cleavage site . Compstatin is a 13-residue cyclic peptide of 1551 Da with sequence:
I C V V Q D W G H H R C T -N H 2 , i s -s '
which contains a disulfide bridge between Cys2 and Cys". Elucidation of the solution structure of free Compstatin is a first step toward understanding the topology and the mechanism of the peptide binding to C3.
Small peptides are, in most cases, present in solution as an ensemble of interconverting conformers (Dyson & Wright, 1991 . In some cases, the population of one or more conformers in the ensemble can be high enough for detection by spectroscopic methods. Cyclic peptides are more restrained in flexibility compared to linear peptides, and they are more likely to demonstrate a preference for an observable conformer. The presence of rapidly interconverting conformers is reflected in the measured NMR parameters, which are population-weighted averages of the individual contributing structures.
In the present study, we have used NMR spectroscopy to extract distance, dihedral angle, and 3JNH.H,-coupling constant restraints (Wiithrich, 1986 ), which we have used for the structure elucidation of a major Compstatin conformer. We utilized a hybrid distance geometry-restrained simulated-annealing methodology (Nilges et al., 1988; Kuszewski et al., 1992) for the structure calculation. Subsequently, we examined the structure for consistency using characteristic NOE connectivities, 3JNH.H,-CoUpling constants, chemical shifts, and temperature dependence of chemical shifts (Wiithrich, 1986; Dyson et al., 1988) . In addition, we analyzed the contribution of each amino acid residue by synthesizing and examining the inhibitory activity of a series of analogue peptides with Ala substitutions. The analogue data, together with the 2D NMR data, indicate that the type I p-turn segment (Gln5-Asp6-Trp7-Gly') plays a significant role in the inhibitory activity of Compstatin.
Results and discussion

NMR assignment and restraints
Proton resonance assignments were made according to standard procedures (reviewed in Wiithrich, 1986) .
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Amino acid spin systems were identified by locating networks of characteristic connectivities in the 2D TOCSY spectrum at 5 "C. Figure 1 shows the assignment of all 13 spin systems of Compstatin. The NH of Ile' is not observable because of fast exchange with the solvent, but the rest of the spin system is shown at w2 = wHa (right panel of Fig. 1 ). In addition, the DQ spectra were very useful for resolving ambiguities and verifying the proton assignments. In particular, a remote cross peak was observed in the DQ spectrum at 0 2 = wNH and w , = wHal + wHa2 for Gly8. This cross peak confirmed the assignment of the two degenerate a-protons of Gly' and resolved the ambiguity at w2 = oNH = 8.47 ppm, which is the frequency of three amide protons (Gln', GIy*, Arg"). Raising the temperature to 10°C introduced small shifts in the resonances of NH protons, a change that allowed us to verify all assignments.
Inspection of the 2D NMR spectra indicated the presence of a set of cross peaks corresponding to the backbone of a single Compstatin conformation. However, some side chains, such as Gln' and Trp7, indicated the presence of additional minor conformations. Measurement of the volumes of the NH' diagonal peaks of Trp' in the 2D NOESY spectrum indicated that the Trp7 ring populated four different conformations with population of 96% for the major side-chain conformer and 4% for the rest. No inter-or intraresidue NOES involving the minor side-chain conformations were found, Fig. 1. A portion of the 500-MHz 2D TOCSY spectrum of Compstatin. All 13 spin systems are identified, and individual spins within the same spin system are connected with lines. The right panel shows the spin system of Ile' originating from the a-proton, because the NH of the first residue in the sequence is not observable due to fast exchange with the solvent. Arrows point to NH-H" cross peaks of Cys' and Cys" outside the limits of the plot. These cross peaks are very weak because their Ha-resonances are close to the solvent water resonance and they are attenuated by the water presaturation scheme of the data acquisition pulse sequence. However, they are present in the J-R NOESY or DQ spectra. Some TOCSY connectivities involving the Arg" NHf and long-range couplings between aromatic and side-chain protons are also shown. Sample conditions are pH 6 and 5 "C. and no conformational exchange cross peaks were found in the ROESY spectrum. For the rest of our analysis, we used the unique backbone cross peaks and the cross peaks of the major side-chain conformer of Gln5 and Trp'.
Sequence-specific and long-range NOE assignments were made using the 200-and 400-ms NOESY and the 200-ms J-R NOESY spectra collected at 5 "C and 10 "C. The J-R NOESY was particularly useful for detecting NOES involving the a-protons of Cys' and Cys'', which are very close to the resonance of water and are "bleached out" by the water suppression scheme of the regular NOESY pulse sequence. 2D ROESY spectra of Compstatin were used to verify the regular NOE assignments that had been made using the 2D NOESY and J-R NOESY spectra. Figure 2A shows the backbone and the disulfide bond of the ensemble of the 21 accepted final refined structures for Compstatin. A turn segment was observed in the best-defined region between residues Gln5 and Gly8. Figure 2B shows the backbone of the average restrained regularized structure of the ensemble for the segment Gln5-Asp6-Trp7-Gly8. The turn segment and the two valines, Val3 and Val4, appeared to be better defined than the rest of the peptide. This difference is due to the lack of a significant number of long-range NOE restraints outside the segment Val3-Gly8. The average Rh4SD of the ensemble of 21 structures for Compstatin was 0.6 8, for the backbone heavy atoms and 1.2 A for all heavy atoms. The statistics for the ensemble of the family of structures and for the average regularized structure are summarized in Table 1 . The program PROCHECK-NMR (Laskowski et al., 1996) was used for structure validation and analysis. We found that 90% of the residues lay in the most favored or additionally favored regions of the Ramachandran plot (Ramachandran et al., 1963) using the average restrained regularized structure of Compstatin.
Structure calculations
The cyclic peptide Compstatin forms a type I @ -t u r n spanning residues Gln5-Asp6-Trp7-Gly8 ( Fig. 2A, B ). The general criteria The disulfide bond is shown in yellow. The rest of the residues are colored with the standard atomic color code for hydrogens (white), nitrogens (blue), carbons (green), and carbonyl oxygens (red).
for the presence of ap-turn are: a C"(1)-C'(4) distance <7 8, and that the central residues are not helical (Chou & Fasman, 1977; Schulz & Schirmer, 1979; Rose et al., 1985; Wilmot & Thornton, 1988) . The presence of a C = O( 1) -HN(4) hydrogen bond is possible, but not necessary for stabilization of the p-turn (Chou & Fasman, 1977) . More specifically, a type I p-turn is characterized by dihedral angles (&,&) = (-60",-90") and ( 4~~4~) = (-90",0") (Venkatachalam, 1968; Richardson, 1981; Rose et al., 1985; Wilmot & Thornton 1988) . Table 2 compares the characteristic dihedral angles and distances for the Type I p-turn of Compstatin with the classic type I p-turn.
Type I p-turns are the most abundant turns in protein and peptide structures, and they are two to three times more common than any of the other major categories, the type I1 or type 111 turns; the rest are very rare (Schulz & Schirmer, 1979; Wilmot & Thornton, 1988) . Position 4 of the Compstatin p-turn is occupied by Gly, which has been found to be by far the most favorable amino acid in the fourth position of a type I turn (Wilmot & Thornton, 1988) . Likewise, position 2 of the p-turn of Compstatin is occupied by Asp, which has been found to be one of the most favorable amino acids in type I p-turns (Wilmot & Thornton, 1988) . Figure 2C shows a space-filling model of the average restrained regularized structure of Compstatin. Long-range spatial contacts of the rings of His' and Trp7 with Gly', Gln5, and Asp6 and of the methyls of Val3 and Val4 with Gln5 and Asp6 are consistent with observed NOEs. A clustering of hydrophobic side chains of Val', Val4, and Trp7 was observed. Calculation of the solvent-accessible area (Lee & Richards, 1971) of Compstatin revealed reduced solvent accessibility for residues Glns and Gly' at the two ends of the p-turn. This is probably the effect of capping of the turn by the rings of Trp7 because of hydrophobic clustering toward the side chains of Val' and Val4. Also, reduced surface accessibility was observed at Cys2 and Cys", presumably because of restriction of the side chains by the disulfide bond.
Consistency of the calculated structures with the NMR parameters
There are several direct Nh4R criteria for the detection of p-turns, such as characteristic NOE connectivities, 3J~~.~,-COUpling constants, temperature coefficients, and chemical shifts (Wiithrich, 1986; Dyson et al., 1988; Dyson &Wright, 1991 . However, in several instances, the presence of multiple peptide conformers can produce an averaging of the NMR parameters that can hinder a straightforward analysis (Dyson et al., 1988) . In these cases, the
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NMR parameters, alone and in the absence of a complete structure calculation, might not be sufficient to detect classical /?-turns, but they should be consistent with the definition of a particular turn type (Wiithrich, 1986) . The consistency of the measured Nh4R parameters with the calculated average structure of Compstatin is discussed below.
In general, the NOEs that are consistent with the presence of p-turns are NH(2)-NH(3), NH(3)-NH(4), HU(2)-NH(3), H"(3)-NH(4), and H"(2)-NH(4) (Wiithrich, 1986 ). In the case of an ideal type I p-turn, strong NH(2)-NH(3) (corresponding to a distance of 2.6 A), NH(3)-NH(4) (2.4 A), medium H"(2)-NH(3) (3.4 A), H"(3)-NH(4) (3.2 A), and weak HU(2)-NH(4) (3.6 A) NOEs are observed. NOEs that distinguish a type I from a type I1 p-turn are: a strong NH(2)-NH(3) NOE (2.6 A) and a medium HU(2)-NH(3) NOE (3.4 A) in an ideal type I p-tum, as opposed to a weak NH(2)-NH(3) NOE (4.5 A) and a strong HU(2)-NH(3) NOE (2.2 A) in an ideal type I1 turn. In the case of Compstain, a strong NH(3)-NH(4) (compared to other NH-NH) NOE was observed between Trp7 and Gly', a finding that is therefore consistent with the presence of a p-turn (type I or II). A strong NH(2)-NH(3) NOE was observed between residues Asp6 and Trp7, indicating the presence of a type I p-turn. The other characteristic of a type I p-turn, a medium H"(2)-NH(3) NOE between Asp6 and Trp7, could not be assigned unambiguously because of overlap with the strong intraresidue Trp7 NH-H" NOE (the H" of Asp' and Trp' were at 4.56 and 4.57 ppm, respectively). Increasing the temperature from 5 "C to 10 "C did not resolve this ambiguity because of the small effect of temperature on a-protons. Finally, for a similar reason, the Ha(2)-NH(4) weak NOE between Asp6 and Gly' could not be distinguished from the medium H"(3)-NH(4) NOE between Trp' and Gly'. More specifically, a medium NOE at (H", NH) = (4.57, 8.47) ppm was observed, which most likely corresponds to the medium expected HU(3)-NH(4) NOE between Trp7 and Gly' (characteristic of a p-turn). This NOE hinders the unambiguous assignment of the expected weak H"(2)-NH(4) NOE between Asp' and Gly8 (also characteristic of a p-turn). This is due to the overlap of the H"-resonances of Asp6 and Trp7. The temperature. increase to 10°C did not resolve this ambiguity. However, an HP(2)-NH(4) very weak NOE between Asp6 and Gly' was observed in the 200-ms NOESY spectrum; this NOE gained significant intensity in the 400-ms NOESY spectrum, where some degree of spin diffusion is present.
In addition to NOES, 3&H.Hu-CoUpling constants can be used to validate the presence of a p-turn (Wiithrich, 1986) . However, 3JNH.Ha-~o~pling constants should only be used in a qualitative (Campbell et al., 1995) . The averaging of '&H.Ha(2) reflects the presence of an equilibrium between different structural conformers. Assuming a twostate model of a p-turn and an extended conformation, a 100% &turn conformer corresponds to 3&H.H,(2) = 4 Hz (or 4 2 = -60") and a 100% extended conformer corresponds to '&.Ha@) = 9 Hz (or 42 < -100"). Using this model and a ' JNH.H,(2) = 6.9 Hz for Asp6 at position 2 of the @-turn ['JNH-H, extracted with the method of Kim and Prestegard (1989) ], we calculated a population for a p-turn conformation of 42%. If we take into account an estimated error of 1 Hz in measuring 3.fNH.H,-coupling constants and the fact that the ' JNH.Ha-COUp1ing constants extracted from DQF-COSY spectra might represent an upper limit of the actual 3JNH.H,-value (see Supplementary material), we estimate that a p-turn population of 42-63% is present in the case of Compstatin.
Deviations of observed chemical shifts from random coil values are indicative of the presence of secondary structure. For a-protons, a mean difference of -0.39 ppm or of +0.37 ppm is indicative of a helical or an extended conformation, respectively (Wishart et al., 1991) . No a-proton chemical shift difference greater than k0.3 ppm was observed for Compstatin. Thus, it appears that there is no strong preference for a helical or extended conformation and that Compstatin is found in a rather flexible conformational environment. In addition, temperature-dependent experiments did not reveal a preference for hydrogen bonding for the NH of Gly8 (residue 4 of the p-turn).
Biological significance and structural determinants important in compstatin-C3 binding
Complement-mediated pathology has been reported in several diseases; thus, a specific complement inhibitor of therapeutic value needs to be developed. However, none is currently available. It is well known that activation of one pathway (classical or alternative or lectin) leads to recruitment of another. For example, activation of the classical pathway results in the activation of the alternative pathway (Men & Pangburn, 1990) . Similarly, activation of the lectin pathway supports the activation of the alternative pathway (Reid & Turner, 1994; Matsushita, 1996) . Thus, in most clinical conditions, multiple pathways are activated. These results suggest the usefulness of a complement inhibitor that blocks all three pathways. The three pathways converge at the C3 activation step; therefore, blocking this step would result in total shut-off of the complement cascade, including generation of C3a and C5a and MAC formation. In fact, many physiological regulators of complement, e.g., factor H, CRI, DAF, and MCP, act on C3b to inhibit complement activation. A soluble form of CRl has been tested and found to suppress complement pathology in a number of in vivo complement-dependent diseases models (Kalli et al., 1994) . HOWever, identifying a smaller biologically active fragment of these regulatory proteins or a peptide mimetic is necessary for structural studies and the rational design of a clinical drug.
In our previous study, we have isolated and functionally characterized a small cyclic C3-binding peptide, Compstatin, that is a potent inhibitor of complement . In the present study, in order to identify the residues essential for Compstatin interaction with C3, we have synthesized an 11-residue peptide that has the sequence of Compstatin, except for Ile' and Thr13, and also generated nine Ala mutants in which each amino acid between Cys2 and Cys" was replaced (we followed the notation of Compstatin after sequence alignment). Replacement of Val4, His', His", and Arg" resulted in minimal change in the functional activity, suggesting that these residues do not contribute significantly to binding with C3 (Table 3) . Replacement of Val3, Gln', Asp6, and Trp7 reduced the activity of the peptide by 6-36-fold. Replacing Gly8 dramatically reduced the activity of the peptide by more than 100-fold. It is interesting that four of these five residues comprise the type I p-turn of Compstatin. The calculated type I p-turn segment (Gln5-Asp6-Trp7-Gly8) is important in preserving the conformational stability of Compstatin and probably plays a significant role in the inhibitory activity. The total loss of biological activity that resulted from replacement of Gly' is probably related to loss of the turn structure. Given the amino acid composition of the turn, Gly' might be needed to release the steric hindrance and stabilize the turn structure. Of the four residues that comprise the type I p-turn, it seems that the two end residues, Gln' and Gly8, which are somehow buried (as demonstrated by the solvent accessibility calculation), are more essential for Compstatin activity. However, the role of Val' in peptide binding is not obvious. As discussed above, a hydrophobic clustering of the side chains of Val', Val4, and Trp' is present in Compstatin. Interaction of the side chain of Val' with Glns and Asp6 are observed in the calculated structure. These interactions might be important in stabilizing the p-turn. The same residues that are involved in side-chain and backbone interactions that stabilize the p-turn are also important for the functional activity of Compstatin. It is possible that disruption of the turn structure can cause loss of inhibitory activity of Compstatin. Further studies examining the structure of the five Ala mutants that significantly decrease the inhibitory activity of Compstatin (see above) are underway.
The possibility that Compstatin undergoes structural reorientation upon binding is open, and studies of the bound peptide are planned. A comparison between the structures of the free and the bound peptide could yield significant insight into the C3-peptide recognition process.
Peptide conformational changes upon binding have been observed by NMR spectroscopy, with a most common case that of the cyclophilin-cyclosporine complex (Weber et al., 1991; Wuthrich et al., 1991) . In the case of cyclosporine complexed to cyclophilin, inversion of the orientation of the dominant hydrophobic cluster and the peptide backbone, together with the presence of intermolecular hydrogen bonding, have been shown to be important for recognition and binding (Weber et al., 1991; Wiithrich et al., 1991) . Likewise, it has been suggested recently that, during the regulation of apoptosis, the Bcl-x= receptor protein undergoes structural re- 
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orientation to expose a hydrophobic segment upon binding of the Bak peptide (Sattler et al., 1997) . The hydrophobic cluster of Compstatin might be mediating hydrophobic interactions with C3 through its binding site. The presence of a negative charge in Asp' at the second position of the &turn and the possible role of this residue in charge-charge interactions during binding, together with hydrogen bonding possibilities involving the side chains of Glns and Asp', are important subjects for further investigation.
Materials and methods
Peptide synthesis, purification, and characterization
Compstatin (peptide I) and its analogues (peptides 11-XI) were synthesized in an Applied Biosystem peptide synthesizer (model 431A) using Fmoc amide resin. The side-chain protecting groups were: Cys(Trt), Asp(otBu), Arg (Pmc), Thr (tBu), Gln (Trt), Trp-(Boc), His(Trt). All peptides were cleaved from the resin by incubation for 3 h at 22°C with a solvent mixture containing 5 % phenol, 5% thioanisole, 5% water, 2.5% ethanedithiol, and 82.5% TFA. The reaction mixture was filtered through a fritted funnel, precipitated with cold ether, dissolved in 50% acetonitrile containing 0.1% TFA, and 1yop;dized. The crude peptides obtained after cleavage were dissolved in 10% acetonitrile containing 0.1% TFA and purified using a reversed-phase C-18 column (Waters, Milford, Massachusetts). Disulfide oxidation of all the purified peptides was performed by stirring a 0.15 mM solution of the peptide in 0.1 M ammonium bicarbonate, pH 8.0, and bubbling with oxygen at 22 "C for 48 h. Purified peptide I1 was reduced and alkylated with IO mM dithiothreitol and 40 mM iodoacetamide. The purity and identity of Compstatin and its analogues were critically monitored by analytical chromatography and laser desorption mass spectrometry (Moore, 1993) . Formation of a disulfide bond in each cyclic peptide was confirmed by mass spectrometry using a mass shift assay that involves reaction of thiols with p-hydroxy mercuribenzoic acid (Angeletti et al., 1996) .
Complement inhibition assay
Inhibition of complement function by Compstatin and analogue peptides was studied by measuring their effect on the alternative pathway of complement. Inhibition of complement activation was determined by measuring the lysis of rabbit erythrocytes (Er) in normal human serum as described previously (Sahu & Pangburn, 1996) . Various concentrations of peptide were mixed with 5 p L of NHS, 5 p L of 0.1 M MgEGTA, and IO p L of Er ( I X 109/mL) and brought to a final volume of 100 p L in GVB (5 mM barbital, 0.1 % gelatin, and 145 mM NaCI, pH 7.4). The reaction mixture was incubated at 37 "C for 20 min and stopped by adding 200 p L of GVBE (GVB with 10 mM EDTA). After centrifugation, lysis of Er was determined at 414 nm. The percentage of lysis obtained was normalized by considering 100% lysis to be equal to the lysis occumng in the absence of the peptide. The concentration of the peptide causing 50% inhibition of hemolytic activity was taken as the ICso.
NMR sample preparation
The NMR samples were prepared by dissolving Compstatin in 0.6 mL of 90% H20/10% D20 containing 0.05 M potassium phosphate, 0.1 M potassium chloride, 0.1% sodium azide, and M EDTA. Compstatin is highly soluble in aqueous solution; solvation to a final concentration of 3 mM was instantaneous. Mass spectroscopy showed the solution to be monomeric. The sample, prepared at pH 6, was highly pure and suitable for NMR spectroscopy. pH 6 was chosen because it is lower than the pH favoring cysteine oxidation-reduction reactions and higher than that favoring hydrolysis at the aspartic acid position. This pH was sufficient to achieve slow amide proton exchange with the solvent in order to facilitate the proton assignments. As assessed by mass spectroscopy and ID NMR spectra, the sample was stable over the period of several days required to collect the 2D NMR spectra. Most experiments were performed at 5°C to slow down the peptide tumbling time and to limit potential exchange between the various peptide conformers and amide proton exchange with the solvent.
NMR data acquisition
NMR spectra of Compstatin were acquired with a Varian Unityplus 500 MHz spectrometer. Standard methods were used to obtain 1D and 2D ' H NMR spectra. These included 2D TOCSY (Braunschweiler & Emst, 1983) , 2D DQF-COSY (Rance et al., 1983) , 2D DQ , 2D NOESY (Kumar et al., 1980) , 2D J-R NOESY (Plateau & GuCron, 1982) , and ROESY (Bothner-By et al., 1984) . Experiments were performed at 5 "C and some were repeated at 10°C. Experimental constraints for structure calculations were extracted from the 5 "C spectra. Mixing times were 150, 200, and 400 ms for the NOESY, 200 ms for the J-R NOESY, 60 ms for the TOCSY, and 150 ms for the ROESY experiments. The excitation period for the DQ experiments was 40 ms.
Conversion of NMR parameters to structural restraints
Cross peak volume integrations were performed with the program FELlX 2.3, using mainly the 150-ms 2D NOESY experiment collected at 5 "C. The NOE volumes were then converted to distance restraints after they were calibrated using known fixed distances of the Trp' ring. The cross peaks corresponding to NH'-CHS and NH'-CHC' NOEs of Trp7 were used as reference for the calibration within the program FELIX 2.3. Then an NOE restraint file was generated with four distance classifications, as follows: strong NOEs involving amide protons was extended to 2.9 8, for strong NOEs and to 3.5 8, for medium NOEs to account for the higher observed intensity of this type of cross peak (Qin et al., 1996) . In addition, a 0.5-8, correction (Qin et a] ., 1996) was added to the upper boundary of the distances involving methyl groups to account for the averaging of the three methyl protons. An NOE restraint between the two sulfur atoms of Cys2 and CysI2 was set during the distance geometry calculation, corresponding to distance 2.02 8,. During structure calculations, distances involving nonstereospecifically assigned or degenerate methylene protons and methyl groups were incorporated as ( % -6 ) -' ' 6 effective distances (Nilges, 1993) . A total of 136 NOE-derived distance restraints were used, 83 intraresidue, 30 backbone-backbone or HP-backbone, and 23 mediumand long-range, corresponding to an average of 10.5 NOEs per residue.
Resolved P-methylene protons were observed only for residues His', Arg", and Cys". Resolved methyl protons were observed for residues Ile' and Val4. Stereospecific assignments were made for the P-methylene protons of His' and Cys'*. Side-chain x,-dihedral angles for the residues involving stereospecific P-methylene proton assignments were restrained to one of the staggered conformations. In the case of His9 and Cys", the value was found to be , y I = -60 * 30", using the combined information from Hn-HP DQF-COSY cross peak patterns and NOE intensities of NH-HP cross peaks.
3JHN.H,-coupling constants were measured from the 2D DQF-COSY spectrum using the method of Kim and Prestegard (1989) . For accurate evaluation of coupling constants, the data were processed without window function weighting, and they were zero filled to 16K points in the tz-dimension. The ' JNH.H,-CoUpling constant of Cys2 was estimated from the 1D 'H NMR spectrum.
The '&~.~,-CoUpling constants corresponded to all residues except Ile'. The calculated coupling constants and their estimated error of 1 Hz were used for direct J-coupling refinement in the final stages of the peptide structure calculation.
Dihedral angles were calculated using the J-values extracted by solving the Karplus equation (Karplus, 1959; Bystrov, 1976) with coefficients A = 6.98, B = -1.38, C = 1.72 (Wang & Bax, 1996) . Only +-angles that correspond to 3&H.H,-CoUpling constants that yielded only two real roots for C$ when solving the Karplus equation (Karplus, 1959) were used. Specifically, for '&H.H, 2 9 Hz, a dihedral angle of C$ = -120 & 40" was used and for 7.9 5 ' J N H -H , < 9 Hz, a dihedral angle of C$ = -120 * 50" was used.
The range was calculated to be +20" and f30" for the two categories, respectively, in order that both solutions of the Karplus equation would be covered with an additional f20" as an error. For 'JNH.Ha 5 7.3 Hz, no C$-angle restraint was used, because all four solutions of the Karplus equation are possible for a turn segment. However, during the direct 3JNH.Ha-coupling constant minimization, we used all evaluated '&H.Ha-COUphg constants and no +-angle restraint.
A total of 7 (of 12 calculated) +-dihedral angle, 2 ,yl-dihedral angle, and 12 3J~~.~,-COUpling constant restraints were used. The 7 +-angles used corresponded to Cys2, Val', Trp7, His', Hislo, Cys'*, and Thr".
Structure calculations
The Compstatin structures were calculated using the hybrid distance geometry-simulated annealing and refinement protocol (Nilges et al., 1988; Kuszewski et al., 1992) , with further direct 3 J~~.~, -coupling refinement (Garrett et al., 1994) using the program X-PLOR 3.851 (Briinger, 1992) . The minimized target function during simulated annealing was composed of quadratic harmonic potential terms for covalent geometry (bonds, angles, planes, chirality), a quartic van der Waals repulsion term for the nonbonded contacts, quadratic square-well potentials for the experimental distance and dihedral angle restraints, and harmonic potential for the '&H.Haaxqding constant restraints (Briinger, 1992; Garrett et al., 1994) . No hydrogen bonding, electrostatic, or 6-12 Lennard-Jones empirical potential energy terms were present in the simulatedannealing target function. A standard quadratic target function was minimized during distance geometry (Briinger, 1992) .
The input force constants for bonds, angles, planes, and chirality were 1,000 kcal mol-' 500 kcal mol-' rad-', 500 kcal mol-' rad-*, and 500 kcal mol-' rad-', respectively, and 4 kcal mol-' for the quartic van der Waals repulsion term. The input NOE, dihedral angle, and 'JHN.Ha-coupling constant force constants were 50 kcal mol" k 2 , 200 kcal mol" rad-2, and 1 kcal mol-' Hzp2, respectively. Force constants were varied during the various steps of the structure calculation according to the standard X-PLOR protocols (Briinger, 1992) .
A total of 100 structures were generated, and those with low energies and with no NOE violation >0.3 A, no dihedral angle violation >5", no bond violation >0.05 A, no angle violation >5", and no improper angle violation >5" were accepted. The accepted NOE and dihedral angle refined structures were then subjected to further minimization using NOE, XI-dihedral angle, and ' JNH.H,-coupling constant restraints, but not +-dihedral angle restraints. This procedure was repeated iteratively to evaluate more distance restraints. A family of structures with similar geometries in the Gln5-Glys region was observed and the best structure with low-energy terms and no 3JNH.H,-~o~pling constant violation > 1.2 Hz was selected for further final refinement.
Coordinates
Coordinates have been deposited with the Brookhaven National Protein Data Bank (code lalp).
Supplementary material in electronic appendix
We have included an Electronic Appendix that contains details relevant to 3JNH.H,-~o~pling constant evaluation (Fig. l) , structure calculation and solvent accessibility (Fig. 2) , and chemical shift analysis (Fig. 3) . 'H NMR chemical shifts of Compstatin are given in Table 1 . The coordinates of the average restrained regularized structure of Compstatin are given in the file acst.pdb.
